Drug Trial Radar · NCT07683325
NOV-ERA - A Clinical Trial to Assess the Efficacy and Safety of Ontunisertib Compared to Placebo in Patients With Fibrostenosing Crohn's Disease
Last checked: Nov 19, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
320
Planned (sponsor's estimate)
Start
Oct 30, 2026
Primary completion
Dec 31, 2028
Study completion Jun 30, 2029
Sponsor
- Lead sponsor
- Agomab Spain S.L.U.Industry
- Sponsor type
- Industry
- First posted
- Jul 6, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Many patients with Crohn's disease (CD) develop fibrotic narrowing (strictures) in their bowel, causing obstructive symptoms such as abdominal pain, cramping, or vomiting after meals. Because of these symptoms, patients often require bowel resection surgery. The objective of this clinical trial is to evaluate the efficacy, safety, and dose-response relationship of ontunisertib in participants with CD and symptomatic strictures, and contribute to the validation of novel endpoints to assess potential treatment benefit in patients with fibrostenosing Crohn's disease (FSCD). The participants will be in the trial for a duration of up to 60 weeks, consisting of a 6-week screening period (with 2 screening visits), a 52-week treatment period, and a 2-week follow-up period. The visit frequency in the treatment period will be every 6 to 8 weeks.
Conditions
- Fibrostenotic Crohn's Disease
Interventions
OntunisertibDrug
Oral capsule
OntunisertibDrug
Oral capsule
OntunisertibDrug
Oral capsule
PlaceboDrug
Matching oral capsule
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants achieving endoscopic passability of the ileal index strictureTime frame: At week 24
Locations
11 sites in 3 countries. Site status is shown where the registry gives one.
GI Alliance
Sun City, Arizona · Recruiting
Synergy Healthcare, LLC
Bradenton, Florida · Recruiting
Albany Gastroenterology Consultants
Albany, New York · Recruiting
University Gastroenterology
Providence, Rhode Island · Recruiting
GI Alliance
Cedar Park, Texas · Recruiting
GI Alliance - Fort Worth
Fort Worth, Texas · Recruiting
Amel Med LLC
Georgetown, Texas · Recruiting
Clinical Hospital Center "Dr. Dragisa Misovic-Dedinje"
Belgrade, Serbia · Recruiting
Clinical Hospital Center Bezanijska Kosa
Belgrade, Serbia · Recruiting
Clinical Hospital Center Zvezdara (CHCZ)
Belgrade, Serbia · Recruiting
Royal London Hospital
London, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.